翻訳と辞書
Words near each other
・ OD600
・ ODA
・ Ocular (disambiguation)
・ Ocular albinism
・ Ocular albinism type 1
・ Ocular dominance
・ Ocular dominance column
・ Ocular dysmetria
・ Ocular flutter
・ Ocular hypertension
・ Ocular immune system
・ Ocular ischemic syndrome
・ Ocular larva migrans
・ Ocular melanosis
・ Ocular micrometer
Ocular myasthenia
・ Ocular neurosis
・ Ocular prosthesis
・ Ocular rosacea
・ Ocular scales
・ Ocular straylight
・ Ocular tonometry
・ Ocular tremor
・ Oculariini
・ Ocularis Infernum
・ Ocularist
・ Oculesics
・ Oculeus
・ Oculina
・ Oculina diffusa


Dictionary Lists
翻訳と辞書 辞書検索 [ 開発暫定版 ]
スポンサード リンク

Ocular myasthenia : ウィキペディア英語版
Ocular myasthenia

Ocular myasthenia gravis (MG) is a disease of the neuromuscular junction resulting in hallmark variability in muscle weakness and fatigability. MG is an autoimmune disease where anomalous antibodies are produced against the naturally occurring acetylcholine receptors in voluntary muscles. MG may be limited to the muscles of the eye (ocular MG), leading to abrupt onset of weakness/fatigability of the eyelids or eye movement. MG may also involve other muscle groups (generalized MG).
==Pathophysiology==
Normally, muscle contraction is a result of electrical signals sent from the central nervous system to muscle fibers via nerve impulses. At the neuromuscular junction, this electrical message is converted into a chemical message as acetylcholine is released from nerve fibers and attaches to corresponding receptors on the muscle fiber.
In MG, antibodies are produced that block acetylcholine receptors, preventing the molecule from binding to the receptor and leading to a breakdown in communication between the nervous system and the muscle, resulting in muscle fatigue, and sometimes paralysis. Autoantibodies against acetylcholine receptors are detectable in 70–90% of patients with generalized MG, but only 50% in ocular MG.

抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)
ウィキペディアで「Ocular myasthenia」の詳細全文を読む



スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース

Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.